Reaction

Glomerular Filtration Rate Abnormal reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,388 reports · 39 co-occurring drugs

As of the last recalculation, Glomerular Filtration Rate Abnormal appears in 1,388 FAERS reports alongside 39 co-occurring drug terms. The strongest observed disproportionality signal is TENOFOVIR DISOPROXIL FUMARATE (PRR 108.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tenofovir Disoproxil Fumarate	204	108.3	109.0
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	69	108.2	108.9
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	47	81.0	81.4
Emtricitabine And Tenofovir Disoproxil Fumarate	208	80.3	80.6
Emtricitabine And Tenofovir Alafenamide	54	74.3	74.6
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	68	59.1	59.3
Voclosporin	19	33.2	33.3
Dolutegravir Sodium	18	30.3	30.4
Eplerenone	23	27.4	27.4
Dapagliflozin	53	26.2	26.3
Torsemide	49	23.0	23.0
Cefazolin	12	19.9	19.9
Daptomycin	12	19.7	19.7
Raltegravir	18	16.5	16.6
Cefazolin Sodium	13	16.3	16.3
Empagliflozin	67	15.6	15.6
Dextrose	12	13.8	13.8
Dextrose Monohydrate	12	13.6	13.6
Rifampin	13	13.5	13.5
Darunavir	13	13.0	13.0
Tolvaptan	12	12.5	12.5
Nebivolol	12	11.4	11.4
Isosorbide Mononitrate	14	10.2	10.2
Ritonavir	18	9.3	9.4
Atovaquone	5	9.3	9.3
Ribociclib	19	9.1	9.1
Nebivolol Hydrochloride	20	9.0	9.0
Abemaciclib	11	8.3	8.3
Tofacitinib Citrate	7	8.0	8.0
Eculizumab	28	7.9	7.9
Linezolid	15	7.6	7.6
Atazanavir	7	7.3	7.3
Velpatasvir And Sofosbuvir	6	7.0	7.0
Tafamidis	4	5.1	5.1
Remdesivir	4	4.5	4.5
Romosozumab-Aqqg	4	4.4	4.4
Sacubitril And Valsartan	30	3.9	3.9
Sarilumab	6	3.4	3.4
Ledipasvir And Sofosbuvir	4	3.1	3.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.